Transporter Interactions

Inhibition of drug transporters by a new chemical entity may alter the disposition of co-medicated drugs, resulting in significant changes in total and local drug exposures. Our drug-drug interaction services include assays for in vitro characterization of the inhibition potential of a new chemical entity towards transporters explicitly recommended in the regulatory guidance (MDR1, BCRP, OATP1B1, OATP1B3, OAT1, OAT2, and OCT2) and some additional transporters with potential clinical relevance (OCT1, MATE1 and MATE2-K). The in vitro data, with estimates on local plasma and tissue concentrations in vivo, can be used to evaluate whether further clinical investigation is advisable.

Our transporter-mediated DDI services are described in more detailed manner on Permeability and Transporters page.